



2018年11月29日 星期四

[首页](#)[期刊概况](#)[编委会](#)[专家学者](#)[网上投稿](#)[过刊浏览](#)[期刊订阅](#)[广告合作](#)

中国肿瘤临床 » 2015, Vol. 42 » Issue (14): 689-694 DOI: doi:10.3969/j.issn.1000-8179.20150501

[基础研究](#)[最新目录](#) | [下期目录](#) | [过刊浏览](#) | [高级检索](#)| [后一篇](#) ►

FAT10通过激活RhoA介导肝细胞性肝癌侵袭转移*

胡威①②, 董忠谊①, 吴德华①

作者单位: ①南方医科大学南方医院放疗科(广州市510515); ②遵义医学院附属医院胸部肿瘤科

FAT 10promotes invasion and metastasis of hepatocellular carcinoma through activating RhoA

Wei HU^{1,2},Zhongyi DONG¹,Dehua WU¹

1Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou 510515, China;

2Department of Thoracic Cancer, Affiliated Hospital of Zunyi Medical College, Zunyi563003, China

[摘要](#)[图/表](#)[参考文献\(0\)](#)[相关文章 \(15\)](#)**全文:**[PDF](#) (1678 KB) [HTML](#) (1 KB)**输出:**[BibTeX](#) | [EndNote](#) (RIS)**摘要**

目的: 探讨FAT 10与肝细胞性肝癌 (hepatocellularcarcinoma , HCC) 恶性病理特征间的相关性, 及FAT 10对细胞骨架蛋白F-actin的影响及可能的机制。方法: 通过免疫组织化学技术检测108 例肝癌组织标本中FAT 10及active-RhoA蛋白表达, 分析它们与患者临床病理特征之间的相关性及二者间的相关性; 用7721、HepG2 肝癌细胞株瞬时转染质粒过表达FAT 10, 用Huh 7 及LM3 细胞株转染siRNA 干扰FAT 10表达, 利用Westernblot方法检测过表达和干扰FAT 10后肝癌细胞中active-、total-RhoA 和ROCK 蛋白表达的变化; 利用免疫荧光检测7721细胞过表达FAT 10后细胞骨架蛋白F-actin 的变化。结果: 免疫组织化学结果及临床数据的相关性分析表明: 高表达FAT 10或active-RhoA均与肝癌转移和复发密切相关 (FAT 10 : 复发P = 0.004 , 转移P = 0.031 ; active-RhoA : 复发P = 0.026 , 转移P = 0.036), 且二者的表达水平之间呈明显正相关 (P < 0.001) ; 生存分析的结果表明: 高表达FAT 10或RhoA组患者预后明显差于各自低表达组 (FAT 10 : P = 0.026 ; active-RhoA : P = 0.019) 。 Westernblot检测显示过表达FAT 10增加active-RhoA和ROCK 蛋白表达; 反之, 干扰FAT 10则抑制active-RhoA和ROCK 蛋白表达 (均P < 0.01) 。免疫荧光显示肝癌细胞株7721过表达FAT 10可促进细胞骨架蛋白F-actin的表达和胞膜聚积及连续性变化。结论: FAT 10与肝癌恶性病理特征密切相关; 并可能通过激活RhoA促进肝癌细胞骨架改变。

服务

- | 把本文推荐给朋友
- | 加入我的书架
- | 加入引用管理器
- | E-mail Alert
- | RSS

作者相关文章

关键词 :[FAT 10](#) , [active-RhoA](#) , [肝细胞性肝癌](#) , [细胞骨架蛋白](#) , [侵袭](#) , [转移](#)**Abstract :**

Objective: To investigate the correlation of FAT 10expression with the malignant characteristics of hepatocellular carcinoma (HCC), and to explore the effect of FAT 10on RhoA and cytoskeleton of HCC. Methods: Immunohistochemistry (IHC) was used to detect the FAT10expression level of 108 HCC patients, and the correlation between the expression of FAT10and the malignant characteristics of HCC patients was analyzed. We transiently transfected plasmids with overexpressed FAT 10using 7721and HepG2 cells or interfered with FAT10expression using siRNA in Huh 7 and LM3 cells. Active-RhoA, total-RhoA, and ROCK protein expression levels were detected by Western blot analysis after overexpression or interference. We also used immunofluorescence to detect changes in the cytoskeleton protein F-actin after FAT10overexpression in7721cells. Results: Correlation analysis showed that both active-RhoA and FAT10expression levels were significantly correlated with clinical malignant characteristics by using IHC (RhoA: metastasis, P=0.036 and recurrence, P=0.026; FAT 10: metastasis, P=0.031 and recurrence P=0.004). In addition, active-RhoA expression level was correlated with FAT10(P=0.000). Survival analysis showed that the prognoses of low-expression active RhoA (P=0.019) or FAT 10(P=0.026) groups were significantly better than those of the high-expression groups. Western blot analysis showed that FAT10 increased the expression of active-RhoA and ROCK. However, the expression of active-RhoA and ROCK decreased after FAT 10interference. F-actin expression increased in the 7721cells with overexpressed FAT 10(all P<0.01). Moreover, FAT10facilitated F-actin aggregation on cell membrane and changes in F- actin. Conclusion:FAT 10is correlated with the malignant characteristics of HCC and may promote changes in HCC cytoskeleton induced by active-RhoA.

Key words :[FAT 10](#) [active-RhoA](#) [hepatocellular carcinoma](#) [cytoskeleton protein](#) [invasion](#) [metastasis](#)

收稿日期: 2015-05-06 出版日期: 2015-07-31

基金资助:

本文课题受遵义医学院联合基金项目(编号:黔科合J 字LKZ[2013] 41号)资助

通讯作者: 吴德华 E-mail: 18602062748@163.com

引用本文:

胡威①②, 董忠谊①, 吴德华①. FAT10通过激活RhoA介导肝细胞性肝癌侵袭转移*[J]. 中国肿瘤临床, 2015, 42(14): 689-694. Wei HU^{1,2},Zhongyi DONG¹,Dehua WU¹. FAT 10promotes invasion and metastasis of hepatocellular carcinoma through activating RhoA. Chinese Journal of Clinical Oncology, 2015, 42(14): 689-694.

链接本文:

<http://www.cjco.cn/CN/doi:10.3969/j.issn.1000-8179.20150501> 或 <http://www.cjco.cn/CN/Y2015/V42/I14/689>

友情链接



版权所有 © 2013 《中国肿瘤临床》编辑部

地址：天津市河西区体院北环湖西路肿瘤医院内 300060

电话/传真：(022)23527053 E-mail: cjco@cjco.cn cjcotj@sina.com 津ICP备09011441号-3